C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology ( ESMO ) Congress 2024 - C4 Therapeutics ( NASDAQ:CCCC )

6 days ago

CFT1946 Is Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities CFT1946 Achieves Dose Proportional Pharmacokinetic Exposure; Successfully Degrades BRAF V600 Mutant Protein Early Evidence of CFT1946 Monotherapy Anti-Tumor Activity in Patients Who Have Progressed on or After BRAF ...

Ticker	Sentiment	Impact
CCCC	Neutral	15 %